HSBC Holdings
RPRX icon

HSBC Holdings’s Royalty Pharma RPRX Stock Holding History

HSBC Holdings’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.8M Sell
1,224,925
-319,093
-21% -$16.6M 0.03% 465
2026
Q1 		$74M Buy
1,544,018
+1,486,020
+2,562% +$65.1M 0.04% 403
2025
Q4 		$2.25M Sell
57,998
-181,710
-76% -$6.93M ﹤0.01% 1518
2025
Q3 		$8.45M Buy
239,708
+203,408
+560% +$7.36M ﹤0.01% 992
2025
Q2 		$1.3M Sell
36,300
-77,498
-68% -$2.57M ﹤0.01% 1670
2025
Q1 		$3.5M Sell
113,798
-58,518
-34% -$1.85M ﹤0.01% 1238
2024
Q4 		$4.38M Sell
172,316
-30,304
-15% -$804K ﹤0.01% 1184
2024
Q3 		$5.69M Sell
202,620
-322,194
-61% -$8.92M ﹤0.01% 1081
2024
Q2 		$13.8M Sell
524,814
-399,619
-43% -$11.1M 0.01% 773
2024
Q1 		$28.1M Buy
924,433
+779,163
+536% +$23M 0.02% 607
2023
Q4 		$4.06M Buy
145,270
+10,893
+8% +$299K ﹤0.01% 1230
2023
Q3 		$3.63M Buy
134,377
+1,682
+1% +$50K ﹤0.01% 1203
2023
Q2 		$4.07M Buy
132,695
+107,591
+429% +$3.64M ﹤0.01% 1137
2023
Q1 		$906K Sell
25,104
-750,073
-97% -$27.8M ﹤0.01% 1805
2022
Q4 		$30.3M Buy
775,177
+308,651
+66% +$12.9M 0.03% 506
2022
Q3 		$18.9M Buy
466,526
+232,534
+99% +$9.93M 0.03% 568
2022
Q2 		$9.82M Buy
+233,992
New +$9.59M 0.01% 909
2021
Q4 		– Sell
-26,164
Closed -$956K – 3338
2021
Q3 		$956K Buy
26,164
+9,217
+54% +$358K ﹤0.01% 1909
2021
Q2 		$700K Buy
+16,947
New +$721K ﹤0.01% 1966
2021
Q1 		– Sell
-18,341
Closed -$899K – 3067
2020
Q4 		$899K Buy
18,341
+12,307
+204% +$522K ﹤0.01% 1769
2020
Q3 		$259K Buy
+6,034
New +$259K ﹤0.01% 2338

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HSBC Holdings's RPRX Position: Q2 2026 in Review

HSBC Holdings reduced its Royalty Pharma (RPRX) stake by 21% in Q2 2026, selling an estimated $16.6M and leaving 1,224,925 shares worth $68.8M. The position accounts for 0.03% of the portfolio, ranked #465.

HSBC Holdings first reported a position in RPRX in Q3 2020 and has held it in 21 quarters since. The position peaked at $74M in Q1 2026. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • HSBC Holdings held 1,224,925 shares of Royalty Pharma worth $68.8M as of Q2 2026.
  • HSBC Holdings sold 319,093 Royalty Pharma shares in Q2 2026, an estimated $16.6M.
  • Royalty Pharma made up 0.03% of HSBC Holdings's portfolio in Q2 2026, its #465 holding.
  • HSBC Holdings first reported a position in Royalty Pharma in Q3 2020 and has held it in 21 quarters since.
  • HSBC Holdings's Royalty Pharma position peaked at $74M in Q1 2026.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.